SEARCH

SEARCH BY CITATION

References

  • Abumrad NN, Barbul A (2004). The use of arginine in clinical practice. In: CynoberLA (ed.). Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition. CRC Press: Boca Raton, FL, pp. 595611.
  • Bachetti T, Comini L, Francolini G, Bastianon D, Valetti B, Cadei M et al. (2004). Arginase pathway in human endothelial cells in pathophysiological conditions. J Mol Cell Cardiol 37: 515523.
  • Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y et al. (2008). Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 26: 11101118.
  • Bainbridge SA, Roberts JM (2008). Uric acid as a pathogenic factor in preeclampsia. Placenta 29 (Suppl. A): S67S72.
  • Bansal V, Ochoa JB (2003). Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care 6: 223228.
  • Becker-Catania SG, Gregory TL, Yang Y, Gau CL, De Vellis J, Cederbaum SD et al. (2006). Loss of arginase I results in increased proliferation of neural stem cells. J Neurosci Res 84: 735746.
  • Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S et al. (2003). Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108: 20002006.
  • Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC (2007). Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol 292: H1340H1351.
  • Boucher JL, Genet A, Vadon S, Delaforge M, Henry Y, Mansuy D (1992). Cytochrome P450 catalyses the oxidation of Nω-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline. Biochem Biophys Res Commun 187: 880886.
  • Boucher JL, Custot J, Vadon S, Delaforge M, Lepoivre M, Tenu JP et al. (1994). Nω-hydroxy-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem Biophys Res Commun 203: 16141621.
  • Bratt JM, Franzi LM, Linderholm AL, Last MS, Kenyon NJ, Last JA (2009). Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol 234: 273280.
  • Bronte V, Zanovello P (2005). Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641654.
  • Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP et al. (1996). Arginase activity in endothelial cells: inhibition by NG-hydroxyarginine during high-output nitric oxide production. Am J Physiol 271: H1988H1998.
  • Castillo L, Chapman TE, Sanchez M, Yu YM, Burke JF, Ajami AM et al. (1993). Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc Natl Acad Sci USA 90: 77497753.
  • Chicoine LG, Paffett ML, Young TL, Nelin LD (2004). Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 287: L60L68.
  • Christianson DW (2005). Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res 38: 191201.
  • Ckless K, Lampert A, Reiss J, Kasahara D, Poynter ME, Irvin CG et al. (2008). Inhibition of arginase activity enhances inflammation in mice with allergic airway disease, in association with increases in protein S-nitrosylation and tyrosine nitration. J Immunol 181: 42554264.
  • Daghigh F, Fukuto JM, Ash DE (1994). Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase. Biochem Biophys Res Commun 202: 174180.
  • Davoodi J, Drown PM, Bledsoe RK, Wallin R, Reinhart GD, Hutson SM (1998). Overexpression and characterization of the human mitochondrial and cytosolic branched-chain aminotransferases. J Biol Chem 273: 49824989.
  • Deignan JL, Livesay JC, Yoo PK, Goodman SI, O'Brien WE, Iyer RK et al. (2006). Ornithine deficiency in the arginase double knockout mouse. Mol Genet Metab 89: 8796.
  • Deignan JL, Livesay JC, Shantz LM, Pegg AE, O'Brien WE, Iyer RK et al. (2007). Polyamine homeostasis in arginase knockout mice. Am J Physiol Cell Physiol 293: C1296C1301.
  • Deignan JL, Marescau B, Livesay JC, Iyer RK, De Deyn PP, Cederbaum SD et al. (2008). Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. Mol Genet Metab 93: 172178.
  • Demougeot C, Prigent-Tessier A, Marie C, Berthelot A (2005). Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 23: 971978.
  • Durante W, Liao L, Peyton KJ, Schafer AI (1997). Lysophosphatidylcholine regulates cationic amino acid transport and metabolism in vascular smooth muscle cells. Role in polyamine biosynthesis. J Biol Chem 272: 3015430159.
  • Durante W, Liao L, Reyna SV, Peyton KJ, Schafer AI (2000). Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle. FASEB J 14: 17751783.
  • Durante W, Liao L, Reyna SV, Peyton KJ, Schafer AI (2001). Transforming growth factor-beta(1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation 103: 11211127.
  • Durante W, Johnson FK, Johnson RA (2007). Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34: 906911.
  • El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M et al. (2008). Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 9: 13991406.
  • Flynn NE, Meininger CJ, Haynes TE, Wu G (2002). The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother 56: 427438.
  • Gao X, Xu X, Belmadani S, Park Y, Tang Z, Feldman AM et al. (2007). TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 27: 12691275.
  • Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L (2003). Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 17: 23282330.
  • Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM (1988). Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 157: 8794.
  • Holowatz LA, Kenney WL (2007). Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 581: 863872.
  • Holtta E, Pohjanpelto P (1982). Polyamine dependence of Chinese hamster ovary cells in serum-free culture is due to deficient arginase activity. Biochim Biophys Acta 721: 321327.
  • Hunter A, Downs CE (1945). The inhibition of arginase by amino acids. J Biol Chem 157: 427446.
  • Huynh N, Harris E, Chin-Dusting J, Andrews K (2009). The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol 156: 8493.
  • Huynh NN, Chin-Dusting J (2006). Amino acids, arginase and nitric oxide in vascular health. Clin Exp Pharmacol Physiol 33: 18.
  • Iyamu EW, Perdew H, Woods GM (2008). Cysteine-iron promotes arginase activity by driving the Fenton reaction. Biochem Biophys Res Commun 376: 116120.
  • Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE et al. (2002). Mouse model for human arginase deficiency. Mol Cell Biol 22: 44914498.
  • Jenkinson CP, Grody WW, Cederbaum SD (1996). Comparative properties of arginases. Comp Biochem Physiol 114B: 107132.
  • Jeyabalan G, Klune JR, Nakao A, Martik N, Wu G, Tsung A et al. (2008). Arginase blockade protects against hepatic damage in warm ischemia-reperfusion. Nitric Oxide 19: 2935.
  • Johnson FK, Johnson RA, Peyton KJ, Durante W (2005). Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288: R1057R1062.
  • Kenny LC, Broadhurst D, Brown M, Dunn WB, Redman CW, Kell DB et al. (2008). Detection and identification of novel metabolomic biomarkers in preeclampsia. Reprod Sci 15: 591597.
  • Kim NN, Christianson DW, Traish AM (2004). Role of arginase in the male and female sexual arousal response. J Nutr 134: 2873S2879S; discussion 2895S.
  • Lange PS, Langley B, Lu P, Ratan RR (2004). Novel roles for arginase in cell survival, regeneration, and translation in the central nervous system. J Nutr 134: 2812S2817S; discussion 2818S–2819S.
  • Lee MY, Tse HF, Siu CW, Zhu SG, Man RY, Vanhoutte PM (2007). Genomic changes in regenerated porcine coronary arterial endothelial cells. Arterioscler Thromb Vasc Biol 27: 24432449.
  • Lewis C, Zhu W, Pavkov ML, Kinney CM, Dicorleto PE, Kashyap VS (2008). Arginase blockade lessens endothelial dysfunction after thrombosis. J Vasc Surg 48: 441446.
  • Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK et al. (2001). Regulatory role of arginase I and II in syntheses of nitric oxide, polyamines and proline in endothelial cells. Am J Physiol 280: E75E82.
  • Li H, Meininger CJ, Hawker JR Jr, Kelly KA, Morris SM Jr, Wu G (2002). Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol 282: R64R69.
  • Lim HK, Lim HK, Ryoo S, Benjo A, Shuleri K, Miriel V et al. (2007). Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol 293: H3317H3324.
  • Loyaga-Rendon RY, Sakamoto S, Beppu M, Aso T, Ishizaka M, Takahashi R et al. (2005). Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis 178: 231239.
  • Maarsingh H, Zuidhof AB, Bos IS, Van Duin M, Boucher JL, Zaagsma J et al. (2008). Arginase inhibition protects against allergen-induced airway obstruction, hyperresponsiveness, and inflammation. Am J Respir Crit Care Med 178: 565573.
  • Marinova GV, Loyaga-Rendon RY, Obayashi S, Ishibashi T, Kubota T, Imamura M et al. (2008). possible involvement of altered arginase activity, arginase type I and type II expressions, and nitric oxide production in occurrence of intimal hyperplasia in premenopausal human uterine arteries. J Pharmacol Sci 106: 385393.
  • Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP (1978). Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.4.1.1.17) by substrate and product analogs. J Am Chem Soc 100: 25512553.
  • Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L et al. (2004). Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 37083714.
  • Mori M (2007). Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 137: 1616S1620S.
  • Mori M, Gotoh T (2000). Relationship between arginase activity and nitric oxide production. In: IgnarroLJ (ed.). Nitric Oxide. Biology and Pathology. Academic Press: San Diego, CA, pp. 199208.
  • Mori M, Gotoh T (2004). Arginine metabolic enzymes, nitric oxide and infection. J Nutr 134: 2820S2825S.
  • Morris SM Jr (2000). Regulation of arginine availability and its impact on NO synthesis. In: IgnarroLJ (ed.). Nitric Oxide. Biology and Pathobiology. Academic Press: San Diego, CA, pp. 187197.
  • Morris SM Jr (2004). Enzymes of arginine metabolism. J Nutr 134: 2743S2747S.
  • Morris SM Jr (2005). Arginine metabolism in vascular biology and disease. Vasc Med 10: S83S87.
  • Morris SM Jr (2006). Arginine: beyond protein. Am J Clin Nutr 83: 508S512S.
  • Morris SM Jr (2007). Arginine metabolism: boundaries of our knowledge. J Nutr 137: 1602S1609S.
  • Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW (2008). Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate 68: 15611569.
  • Nelin LD, Chicoine LG, Reber KM, English BK, Young TL, Liu Y (2005). Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am J Respir Cell Mol Biol 33: 394401.
  • Palmer RMJ, Ashton DS, Moncada S (1988). Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664666.
  • Reid KM, Tsung A, Kaizu T, Jeyabalan G, Ikeda A, Shao L et al. (2007). Liver I/R injury is improved by the arginase inhibitor, N(omega)-hydroxy-nor-L-arginine (nor-NOHA). Am J Physiol Gastrointest Liver Physiol 292: G512G517.
  • Rodriguez PC, Ochoa AC (2008). Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180191.
  • Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M et al. (2008). Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95102.
  • Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D et al. (2006). Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99: 951960.
  • Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, Sikka G et al. (2008). Endothelial arginase II. A novel target for the treatment of atherosclerosis. Circ Res 102: 923932.
  • Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M et al. (2007). Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res 101: 692702.
  • Santhanam L, Christianson DW, Nyhan D, Berkowitz DE (2008). Arginase and vascular aging. J Appl Physiol 105: 16321642.
  • Schnorr O, Brossette T, Momma TY, Kleinbongard P, Keen CL, Schroeter H et al. (2008). Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Arch Biochem Biophys 476: 211215.
  • Selamnia M, Mayeur C, Robert V, Blachier F (1998). Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Biochem Pharmacol 55: 12411245.
  • Shi O, Morris SM Jr, Zoghbi H, Porter CW, O'Brien WE (2001). Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 21: 811813.
  • Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G (2000). Arginase activity in human breast cancer cell lines: Nω-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 60: 33053312.
  • Stanley KP, Chicoine LG, Young TL, Reber KM, Lyons CR, Liu Y et al. (2006). Gene transfer with inducible nitric oxide synthase decreases production of urea by arginase in pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 290: L298L306.
  • Suschek CV, Schnorr O, Hemmrich K, Aust O, Klotz LO, Sies H et al. (2003). Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation 107: 26072614.
  • Tasaki T, Kwon YT (2007). The mammalian N-end rule pathway: new insights into its components and physiological roles. Trends Biochem Sci 32: 520528.
  • Thengchaisri N, Hein TW, Wang W, Xu X, Li Z, Fossum TW et al. (2006). Upregulation of arginase by H2O2 impairs endothelium-dependent nitric oxide-mediated dilation of coronary arterioles. Arterioscler Thromb Vasc Biol 26: 20352042.
  • Topal G, Brunet A, Walch L, Boucher JL, David-Dufilho M (2006). Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther 318: 13681374.
  • Wei LH, Jacobs AT, Morris SM Jr, Ignarro LJ (2000). IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol 279: C248C256.
  • Wei LH, Wu G, Morris SM Jr, Ignarro LJ (2001). Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci USA 98: 92609264.
  • Wu G, Meininger CJ (1995). Impaired arginine metabolism and NO synthesis in coronary endothelial cells of the spontaneously diabetic BB rat. Am J Physiol 269: H1312H1318.
  • Wu G, Morris SM Jr (1998). Arginine metabolism: nitric oxide and beyond. Biochem J 336: 117.
  • Wu G, Morris SM Jr (2004). Arginine metabolism in mammals. In: CynoberLA (ed.). Metabolic and Therapeutic Aspects of Amino Acids in Clinical Nutrition. CRC Press: Boca Raton, FL, pp. 153167.
  • Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL (1996). Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 93: 67706774.
  • Xu L, Hilliard B, Carmody RJ, Tsabary G, Shin H, Christianson DW et al. (2003). Arginase and autoimmune inflammation in the central nervous system. Immunology 110: 141148.
  • Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T et al. (2004). Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18: 17461748.
  • Yang L, Lewis CM, Chandrasekharan UM, Kinney CM, Dicorleto PE, Kashyap VS (2006a). Arginase activity is increased by thrombin: a mechanism for endothelial dysfunction in arterial thrombosis. J Am Coll Surg 203: 817826.
  • Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmmermann N, Mahalingam S et al. (2006b). Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol 177: 55955603.
  • Yang Z, Ming XF (2006). Endothelial arginase: a new target in atherosclerosis. Curr Hypertens Rep 8: 5459.
  • Zhang C, Hein TW, Wang W, Chang CI, Kuo L (2001). Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 15: 12641266.
  • Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM et al. (2004). Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 44: 935943.
  • Zharikov SI, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER et al. (2008). Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 295: C1183C1190.